Table 2

Main clinical features and treatment outcome of sAPL patients

Patient no.Age (y) at time of APL diagnosisSexAPL characteristics
Therapy of APLOutcome
WBC, ×109/LPLT, ×109/LDIC, Yes/No
UPN 1 60 5.5 25 Yes PETHEMA APL 2005 Died at 7 months due to cerebral hemorrhage 
UPN 2 59 8.9 74 Yes GIMEMA AIDA protocol CCR 21 mo 
UPN 3 58 0.5 37 No PETHEMA APL 2005 CCR 16 mo 
UPN 4 36 0.8 74 No GIMEMA AIDA protocol CCR 16 mo 
UPN 5 26 1.1 30 Yes GIMEMA AIDA protocol CCR 24 mo 
UPN 6 59 1.1 58 Yes GIMEMA AIDA protocol CCR 19 mo 
UPN 7 28 0.7 No UK MRC protocol Relapse at 28 mo 
UPN 8 61 3.3 31 No PETHEMA APL 2005 CCR 4 mo 
UPN 9 45 13 12 No GIMEMA AIDA protocol CCR 4 mo 
UPN 10 27 33.7 11 Yes GIMEMA AIDA protocol CCR 10 mo 
UPN 11 45 0.6 66 No GIMEMA AIDA protocol CCR 10 mo 
UPN 12 67 1.1 No PETHEMA APL 2005 CCR 9 mo 
UPN 13 55 8.9 13 Yes NA Died 3 h after APL diagnosis 
UPN 14 45 72.2 40 Yes PETHEMA APL 2005 CCR 1 mo 
Patient no.Age (y) at time of APL diagnosisSexAPL characteristics
Therapy of APLOutcome
WBC, ×109/LPLT, ×109/LDIC, Yes/No
UPN 1 60 5.5 25 Yes PETHEMA APL 2005 Died at 7 months due to cerebral hemorrhage 
UPN 2 59 8.9 74 Yes GIMEMA AIDA protocol CCR 21 mo 
UPN 3 58 0.5 37 No PETHEMA APL 2005 CCR 16 mo 
UPN 4 36 0.8 74 No GIMEMA AIDA protocol CCR 16 mo 
UPN 5 26 1.1 30 Yes GIMEMA AIDA protocol CCR 24 mo 
UPN 6 59 1.1 58 Yes GIMEMA AIDA protocol CCR 19 mo 
UPN 7 28 0.7 No UK MRC protocol Relapse at 28 mo 
UPN 8 61 3.3 31 No PETHEMA APL 2005 CCR 4 mo 
UPN 9 45 13 12 No GIMEMA AIDA protocol CCR 4 mo 
UPN 10 27 33.7 11 Yes GIMEMA AIDA protocol CCR 10 mo 
UPN 11 45 0.6 66 No GIMEMA AIDA protocol CCR 10 mo 
UPN 12 67 1.1 No PETHEMA APL 2005 CCR 9 mo 
UPN 13 55 8.9 13 Yes NA Died 3 h after APL diagnosis 
UPN 14 45 72.2 40 Yes PETHEMA APL 2005 CCR 1 mo 

DIC indicates disseminated intravascular coagulation; CCR, continuous complete remission; and NA, not applicable.

Close Modal

or Create an Account

Close Modal
Close Modal